The Karnataka Medical Services Corporation Limited (KMSCL) dismantles its in-house drug quality control wing and shifts responsibility for drug quality oversight to the State Drugs Control department. The change means the state department will supervise the quality of medicines procured and handled through KMSCL.
Both outlets report that the move is aimed at replacing KMSCL’s internal quality checks with external oversight. The Times of India describes it as a step for the Drugs Control department to take over medicine quality supervision after KMSCL plans to abolish its quality control wing. The Hindu similarly states that the division responsible for drug quality control at KMSCL is dismantled and that the State Drugs Control department assumes the relevant responsibilities.
While the coverage aligns on the core operational change—ending KMSCL’s internal quality control function and transferring that role to the State Drugs Control department—the outlets present it with slightly different emphasis: one highlights the abolition of the wing, while the other focuses on transferring quality assurance responsibilities. The reporting does not provide detailed timelines or specific procedural changes beyond the shift in oversight authority.
